A new model of time scheme for progression of colorectal cancer

BMC Systems Biology

Volumn 8, Issue 3, 2014, Pages

  Sun, Shuhao ^a   Klebaner, Fima ^a   Tian, Tianhai ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MODEL; CARCINOGENESIS; COLORECTAL TUMOR; DISEASE COURSE; GENETICS; HUMAN; MUTATION; PANCREAS TUMOR; PATHOLOGY; TIME; TUMOR VOLUME;

CARCINOGENESIS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; HUMANS; MODELS, BIOLOGICAL; MUTATION; PANCREATIC NEOPLASMS; TIME FACTORS; TUMOR BURDEN;

EID: 84931037194     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-8-S3-S2     Document Type: Article

References (55)

1. Jones S, dong Chen W, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW, Vogelstein B, Willis J, Markowitz SD: Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA. 2008, 105: 4283-4288. 10.1073/pnas.0712345105.
2. Parsons D, Jones S, Zhang X, Lin J, Leary R, Angenendt P: An integrated genomic analysis of human glioblastoma multiforme. Sciences. 2008, 321: 1807-1812. 10.1126/science.1164382.
3. Seshagiri S: recurrent R-spondin fusion in colon cancer. Nature. 2012, 488: 660-664. 10.1038/nature11282.
4. Sjöblom T, Jones S, Wood L, Parsons D, Lin J: The Consensus Coding Sequences of Human Breast and Colorectal Cancers. Science. 2006, 314: 268-274. 10.1126/science.1133427.
5. Thiagalingam S: Evaluation of chromosome 18q in colorectal cancers. Nat Genet. 1996, 139: 343-346.
6. Samuels Y, Velculescu V: Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004, 3: 1221-1224. 10.4161/cc.3.10.1164.
7. Baker S: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989, 244: 217-221. 10.1126/science.2649981.
8. Armitage P, Doll R: The age distribution of cancer and a multi-stage theory of carcinogenesis. Brit J Cancer. 1954, 8: 1-12. 10.1038/bjc.1954.1.
9. Armitage P, Doll R: A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Brit J Cancer. 1957, 11: 161-169. 10.1038/bjc.1957.22.
10. Attolini C, Michor F: Evolutionary theory of cancer. Ann NY Acad Sci. 2009, 1168: 23-51. 10.1111/j.1749-6632.2009.04880.x.
11. Byrne H: Dissecting cancer through mathematics: from the cell to the animal model. Nat Rev Cancer. 2010, 10: 221-230. 10.1038/nrc2808.
12. Fisher J, Hollomon J: A hypothesis for the origin of cancerfoci. Cancer. 1951, 4: 916-918. 10.1002/1097-0142(195109)4:5<916::AID-CNCR2820040504>3.0.CO;2-7.
13. Foo F, leder K, Michor F: Stochastic dynamics of cancer initiation. Phys Biol. 2011, 8: 1478-1502.
14. Komarova N: Mathematical modeling of tumorigenesis: mission possible. Curr Opin Oncol. 2005, 17: 39-43. 10.1097/01.cco.0000143681.37692.32.
15. Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler K: Genetic progression and the waiting time to cancer. PloS Comput Biol. 2007, 39: 2239-2246.
16. Rick D, Schmidt D, Schweinsberg J: A waiting time problem arising from the study of multi-stage carcinigensis. ANN APPL PROBAB. 2009, 19: 676-718. 10.1214/08-AAP559.
17. Frank S: Dynamics of Cancer: Incidence, Inheritance, and Evolution. 2007, Oxford: Princeton University Press
18. Ritter G, Wilson R, Pomper F, Burmistrov D: The multistage model of cancer develpment: some implications. Toxicol Ind Health. 2003, 19: 125-145. 10.1191/0748233703th195oa.
19. Meza R, Hazelton W, Colditz G, Moolgavkar S: Analysis of lung cancer incidence in the nurses' health and the health professionals' follow-up studies using a multistage carcinogenesis model. Cancer Causes and Control. 2008, 19: 317-328. 10.1007/s10552-007-9094-5.
20. Nowak M, Michor F, Iwasa Y: The linear process of somatic evolution. Proc Natl Acad Sci USA. 2003, 100: 14966-14969. 10.1073/pnas.2535419100.
21. Vineis P, Schatzkin A, Potter JD: Models of carcinogenesis: an overview. Carcinogenesis. 2010, 31: 1703-1709. 10.1093/carcin/bgq087.
22. Iwasa Y, Michor F, Komarova N, Nowak M: Population genetics of tumor suppressor genes. J Theor Biol. 2005, 233: 15-23. 10.1016/j.jtbi.2004.09.001.
23. Meza R, Jeon J, Moolgavkar S, Luebeck E: Age-specific incidence of cancer: Phases, transitions, and biological implications. Proc Natl Acad Sci USA. 2008, 105: 16284-16289. 10.1073/pnas.0801151105.
24. Meza R, Jeon J, Renehan AG, Luebeck EG: Colorectal Cancer Incidence Trends in the United States and United Kingdom: Evidence of Right- to Left-Sided Biological Gradients with Implications for Screening. Cancer Res. 2010, 70: 5419-5472. 10.1158/0008-5472.CAN-09-4417.
25. Su-Chan P, damien Simon, Krug J: The speed of evolution in large asexual population, Journal of Statistical Physics. J Stat Phys. 2010, 138: 381-410. 10.1007/s10955-009-9915-x.
26. Nowak M: Evolutionary Dynamics. 2008, Oxford: The Belknap Press of Harvard University Press
27. Nowak M, Michor F, Iwasa Y: Genetic instability and clonal expansion. J Theor Biol. 2006, 241: 26-32. 10.1016/j.jtbi.2005.11.012.
28. Connolly R, Kimbell J: Simulation of cell growth governed by stochastic processes: application to clonal growth cancer models. YTAAP. 1994, 124: 284-295.
29. Portier CJ, Sherman C, Kopp-Schmeider A: A multistage stochastic models of the cancer process: A general theory for calculating tumor incidence. STOCH ENV RES RISK A. 2000, 14: 173-179. 10.1007/PL00009780.
30. Tian T, Olson S, Whitacre J, Harding A: The origins of cancer robustness and evolvability. Integrative Biology. 2011, 3: 17-30. 10.1039/c0ib00046a.
31. Luebeck E, Moolgavkar S: Multistage carcinogenesis and the incidence of colorectal cancer. Proc Natl Acad Sci USA. 2002, 99: 15095-15100. 10.1073/pnas.222118199.
32. Schinazi R: A stochastic model for cancer risk. Genetics. 2006, 174: 545-547. 10.1534/genetics.106.059295.
33. Knudson A: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971, 68: 820-823. 10.1073/pnas.68.4.820.
34. Knudson A: Two genetic hits (more or less)to cancer. Nat Rev Cancer. 2001, 1: 157-162. 10.1038/35101031.
35. Nordling C: A new theory on cancer-inducing mechanism. Cancer Res. 1953, 7: 68-72.
36. Zeig-Owens R, Gershman S, Knowlton R, Jacobson J: Survival and time interval from surgery to start of chemotherapy among colon cancer patients. J Registry Manag. 2009, 36: 30-41.
37. Berenblum I, Shubik P: A new quantitative approach to the study of the stages of chemical carcinogenesis in the mouse's skin. Brit J Cancer. 1949, 1: 383-391.
38. Frank S: Age-specific acceleration of cancer. Curr Biol. 2004, 14: 242-246. 10.1016/j.cub.2003.12.026.
39. Kingman J: The first birth problem for an age-dependent branching process. Ann prob. 1975, 3: 790-801. 10.1214/aop/1176996266.
40. Moolgavkar S, Luebeck E: Multistage carcinogenesis: population-based model for colon cancer. Cancer Res. 1992, 84: 610-618.
41. Stransky B, de Souza SJ: Modeling tumor evolutionary dynamics. Front Physiol Comput Physio Medicine. 2013, 3: 1-6.
42. Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, Karchin R, Kinzler K, Vogelstein B, Nowak M: Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA. 2010, 107: 18545-18550. 10.1073/pnas.1010978107.
43. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA: Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer. Nature. 2010, 467: 1114-1117. 10.1038/nature09515.
44. Sun SH, Klebaner F, Tian T: A new model for progression of colorectal cancer. 2013 IEEE International Conference on Bioinformatics and Biomedicine, (SCI 2013), Shanghai, China, 18-23 Decenber 2013. 2013, Shanghai, China: International Bioinformatics and Biomedicine, 560-565.
45. Beerenwinkel N, Sullivant S: Markov models for accumulating mutations. J Theor Biol. 2008, 242: 409-420.
46. Beerenwinkel N, Eriksson N, Sturmfels B: Conjunctive Bayesian networks. Bernoulli. 2007, 13: 893-909. 10.3150/07-BEJ6133.
47. Rahnenfuhrer J, Beerenwinkel N, Schulz W, Hartmann C, von Deimling A: Estimating cancer survival and clinical outcome based on genetic tumor progression scores. Bioinformatics. 2005, 21: 2438-2446. 10.1093/bioinformatics/bti312.
48. Wood L, Parsons D, Jones S, Lin J, Sjoblom T, Leary R: The genomic landscapes of human breast and colorectal cancers. Science. 2007, 318: 1108-1113. 10.1126/science.1145720.
49. genome Atlas network TC: Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012, 487: 330-337. 10.1038/nature11252.
50. Jackson A, Loeb L: The Mutation Rate and Cancer. Genetics. 1998, 148: 1483-1490.
51. Bozic I, Reiter J, Allen B, Antal T, Chatterjee K, Shah P, Moon Y, Yaqubie A, Kelly N, Le D, Lipson E, Chapman P, Jr LD, Vogelstein B, Nowak MA: Evolutionary dynamics of cancer in response to targeted combination therapy. eLife. 2013, 2: e00747-
52. Reiter J, Bozic I, Allen B, Chatterjee K, Nowak M: The effect of one additional driver mutation on tumor progression. Evol Appl. 2013, 6: 34-45. 10.1111/eva.12020.
53. Sawyers C: Targeted cancer therapy. Nature. 2004, 432: 294-297. 10.1038/nature03095.
54. Imai K, Takaoka A: Comparing antibody and smallmolecule therapies for cancer. Nat Rev Cancer. 2006, 6: 714-727. 10.1038/nrc1913.
55. Bozicl I, Allen B, Nowak MA: Dynamics of targeted cancer therapy, Trends in Molecular Medicine. Trends Mol Med. 2012, 18: 311-316. 10.1016/j.molmed.2012.04.006.